行情

FSTX

FSTX

F-star Therapeutics Inc
NASDAQ

实时行情|Nasdaq Last Sale

3.970
+0.070
+1.79%
已收盘, 16:00 01/24 EST
开盘
3.900
昨收
3.900
最高
3.990
最低
3.510
成交量
35.94万
成交额
--
52周最高
15.50
52周最低
3.510
市值
8,187.92万
市盈率(TTM)
-0.5789
分时
5日
1月
3月
1年
5年
F-star Therapeutics gets US patent for antibody FS118
F-star Therapeutics (FSTX +3.7%) said the U.S. Patent and Trademark Office granted a patent protecting the composition of matter of the company's tetravalent bispecific antibody FS118, which blocks PD-L1 and LAG-3
Seekingalpha · 4天前
F-star Announces Issuance Of US Patent Protecting FS118, A Bispecific Antibody Targeting PD-L1 And LAG-3
Provides U.S. Patent Protection to at least August 2038 Expands Patent Protection for FS118 Composition of Matter beyond Europe CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- F-star
Benzinga · 4天前
BRIEF-F-Star Announces Issuance Of U.S. Patent Protecting Fs118, A Bispecific Antibody Targeting Pd-L1 And Lag-3
reuters.com · 4天前
F-star Announces Issuance of U.S. Patent Protecting FS118, a Bispecific Antibody Targeting PD-L1 and LAG-3
Provides U.S. Patent Protection to at least August 2038 Expands Patent Protection for FS118 Composition of Matter beyond Europe CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-s...
GlobeNewswire · 4天前
F-star Therapeutics Secures US Patent for FS118 Bispecific Antibody
MT Newswires · 4天前
BRIEF-F-Star Therapeutics Announces Merck KGaA, Darmstadt, Germany Exercises A Fourth Licensing Option In Immuno-Oncology Collaboration
reuters.com · 01/05 13:07
F-star Therapeutics Announces Merck KGaA, Darmstadt, Germany Exercises a Fourth Licensing Option in Immuno-Oncology Collaboration
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives...
GlobeNewswire · 01/05 13:00
Peering Into F-star Therapeutics Recent Short Interest
F-star Therapeutics Inc. - Common Stock's (NASDAQ:FSTX) short percent of float has fallen 90.16% since last its last report. The company recently reported that it has 108.00 thousand shares sold short, which is 0.67% of all regular shares that are availabl...
Benzinga · 2021/12/31 18:13
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解FSTX最新的财务预测,通过FSTX每股收益,每股净资产,每股现金流等数据分析F-star Therapeutics Inc近期的经营情况,然后做出明智的投资选择。
分析师评级

7位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

57.14%强力推荐
42.86%买入
0.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测FSTX价格均价为29.67,最高价位35.00,最低价为15.00。
最高35.00
均价29.67
最低15.00
现价3.970
EPS
实际EPS
预期EPS
-1.68-1.26-0.84-0.42
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
机构持股
总机构数: 70
机构持股: 1,217.76万
持股比例: 59.04%
总股本: 2,062.45万
类型机构数股数
增持
12
17.56万
建仓
4
1.64万
减持
11
67.43万
平仓
8
60.58万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+1.12%
制药与医学研究
-0.55%
高管信息
Non-Executive Chairman/Independent Director
Nessan Bermingham
President/Chief Executive Officer/Director
Eliot Forster
Chief Financial Officer/Treasurer
Darlene Deptula-Hicks
Chief Scientific Officer
Neil Brewis
Other
Louis Kayitalire
Independent Director
David Arkowitz
Independent Director
Edward Benz
Independent Director
Todd Brady
Independent Director
Pamela Klein
Independent Director
Patrick Johan Hendrik Krol
Independent Director
Geoffrey Race
暂无数据
FSTX 简况
F-Star Therapeutics Inc是一家临床阶段的生物制药公司。该公司正在开发免疫疗法,以改变癌症患者的生活。该公司的FS118是主要候选产品,目前正在PD-1/PD-L1获得性耐药头颈癌患者中进行II期试验。该公司还在晚期癌症患者的1期临床试验中开发FS120、FS222 和SB 11285。FS120是一种双特异性天然抗体,可与OX40和CD137结合。FS120是一种双重共刺激抗体或激动剂,通过激活CD137和OX40来打击免疫激活的气体。FS222被开发用于靶向共刺激CD137和抑制性PD-L1受体,这些肿瘤类型包括非小细胞肺癌、卵巢癌和结肠直肠癌和食道癌等胃肠道癌症。SB 1128是一种免疫治疗型合成环状二核苷酸,用于特定癌症的治疗。

微牛提供F-Star Therapeutics Inc(NASDAQ-FSTX)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的FSTX股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易FSTX股票基本功能。